Tumor Biology

, Volume 36, Issue 12, pp 9511–9516 | Cite as

Promoter hypermethylation of the cysteine protease RECK may cause metastasis of osteosarcoma

  • Leisheng Wang
  • Junbo Ge
  • Tian Ma
  • Yanpin Zheng
  • Shiqiao Lv
  • Yu Li
  • Shaoxian Liu
Research Article

Abstract

The present study examined the role of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) promoter hypermethylation as a causative factor in metastasis of osteosarcoma. Using human pathological samples, it is demonstrated that RECK, a cysteine protease that reversibly regulates expression of matrix metalloproteases like matrix metallopeptidase 9 (MMP9), is transcriptionally inhibited in osteosarcoma, especially metastatic variants. This result comes from its promoter hypermethylation, as evaluated in the present study by methylation-specific PCR reaction. The expression of RECK was also significantly diminished in the metastatic variants of osteosarcoma. This downregulation of RECK in advanced grades of osteosarcoma and metastatic grades was also associated with the increased expression of invadosome-specific markers like MMP9, phospho-FAK, and integrins, suggesting the complex contributions of RECK in the prevention of metastasis and its downregulation as a causative factor in osteosarcoma metastasis.

Keywords

RECK Promoter hypermethylation Metastasis Bone tumors Osteosarcoma 

Notes

Acknowledgments

Conflicts of interest

None

References

  1. 1.
    Chang L, Asatrian G, Dry SM, James AW. Circulating tumor cells in sarcomas: a brief review. Med Oncol. 2015;32:430.CrossRefPubMedGoogle Scholar
  2. 2.
    Kim SS, Park YK. Significance of MTA1 in the molecular characterization of osteosarcoma. Cancer Metastasis Rev. 2014;33:981–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Ren L, Khanna C. Role of ezrin in osteosarcoma metastasis. Adv Exp Med Biol. 2014;804:181–201.CrossRefPubMedGoogle Scholar
  4. 4.
    Yang G, Yuan J, Li K. EMT transcription factors: implication in osteosarcoma. Med Oncol. 2013;30:697.CrossRefPubMedGoogle Scholar
  5. 5.
    Li H, Zhang K, Liu LH, Ouyang Y, Bu J, Guo HB. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma. Tumour Biol. 2014;35:5487–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Poudel B, Kim DK, Ki HH, Kwon YB, Lee YM, Kim DK. Downregulation of ERK signaling impairs U2OS osteosarcoma cell migration in collagen matrix by suppressing MMP9 production. Oncol Lett. 2014;7:215–8.PubMedGoogle Scholar
  7. 7.
    Sun D, Wang X, Zhang H, Deng L, Zhang Y. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int. 2011;35:569–74.CrossRefPubMedGoogle Scholar
  8. 8.
    Clark JC, Akiyama T, Thomas DM, Labrinidis A, Evdokiou A, Galloway SJ, et al. RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. Cancer. 2011;117:3517–28.CrossRefPubMedGoogle Scholar
  9. 9.
    Xu J, Wu S, Shi X. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma. J Orthop Res. 2010;28:1621–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Kang HG, Kim HS, Kim KJ, Oh JH, Lee MR, Seol SM, et al. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res. 2007;25:696–702.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang C, Ling Y, Zhang C, Xu Y, Gao L, Li R, et al. The silencing of RECK gene is associated with promoter hypermethylation and poor survival in hepatocellular carcinoma. Int J Biol Sci. 2012;8:451–8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lu XX, Zhang SM, Fang Y, Wang ZT, Xie JJ, Zhan Q, et al. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Tumour Biol. 2013;34:3339–43.CrossRefPubMedGoogle Scholar
  13. 13.
    Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398–406.CrossRefPubMedGoogle Scholar
  14. 14.
    Noda M, Rodan GA. Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res. 1989;21:71–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Baptista AM, Camargo AF, Filippi RZ, Oliveira CR, Azevedo Neto RS, Camargo OP. Correlation between the expression of VEGF and survival in osteosarcoma. Acta Ortop Bras. 2014;22:250–5.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Leisheng Wang
    • 1
    • 2
  • Junbo Ge
    • 2
  • Tian Ma
    • 3
  • Yanpin Zheng
    • 1
  • Shiqiao Lv
    • 2
  • Yu Li
    • 2
  • Shaoxian Liu
    • 2
  1. 1.Department of Orthopedics, Qihu HospitalShandong UniversityJinanChina
  2. 2.Department of OrthopedicsYantaishan HospitalYantaiChina
  3. 3.Department of OrthopedicsThe People’s Hospital of QixiaQixiaChina

Personalised recommendations